SVA — Sinovac Biotech Income Statement
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Annual income statement for Sinovac Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 246 | 511 | 19,375 | 1,493 | 448 |
| Cost of Revenue | |||||
| Gross Profit | 214 | 443 | 18,303 | 808 | 267 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 177 | 295 | 1,822 | 1,959 | 1,051 |
| Operating Profit | 68.6 | 216 | 17,553 | -466 | -603 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 70.8 | 217 | 17,563 | 25.2 | -153 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 65.2 | 185 | 14,459 | 88.1 | -258 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 44.9 | 110 | 8,467 | 114 | -99.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 39.8 | 104 | 8,461 | 108 | -106 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.365 | 0.919 | 74.2 | 0.975 | -0.549 |